Can combined des and lhrh depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
- 31 August 1988
- Vol. 32 (2) , 137-140
- https://doi.org/10.1016/0090-4295(88)90316-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormonesBMJ, 1986
- COMBINED TREATMENT WITH LHRH AGONIST AND PURE ANTIANDROGEN IN ADVANCED CARCINOMA OF PROSTATEThe Lancet, 1984
- Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.BMJ, 1984
- DISEASE FLARE INDUCED BY D-Trp6-LHRH ANALOGUE IN PATIENTS WITH METASTATIC PROSTATIC CANCERThe Lancet, 1984
- Long Term Effects of Administration of a Gonadotropin Releasing Hormone Superagonist Analog in Men with Prostatic CarcinomaJournal of Clinical Endocrinology & Metabolism, 1984
- New prostate cancer drugs: few CV effects?Published by American Medical Association (AMA) ,1983
- Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.Journal of Clinical Investigation, 1983
- Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.BMJ, 1983
- Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.BMJ, 1983
- SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMAThe Lancet, 1982